| Literature DB >> 33382671 |
Kathleen Dooling, Mona Marin, Megan Wallace, Nancy McClung, Mary Chamberland, Grace M Lee, H Keipp Talbot, José R Romero, Beth P Bell, Sara E Oliver.
Abstract
The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use.† On December 1, ACIP recommended that 1) health care personnel§ and 2) residents of long-term care facilities¶ be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (2). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non-health care workers), and that in Phase 1c, persons aged 65-74 years, persons aged 16-64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP's recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33382671 PMCID: PMC9191902 DOI: 10.15585/mmwr.mm695152e2
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 35.301
Advisory Committee on Immunization Practices recommendations for allocation of COVID-19 vaccines to persons aged ≥16 years — United States, December 2020
| Phase | Groups recommended to receive COVID-19 vaccine | No. (millions) | ||
|---|---|---|---|---|
| Total persons in each group* | Unique persons in each group† | Unique persons in each phase | ||
| 1a | Health care personnel | 21 | 21 | 24 |
| Long-term care facility residents | 3 | 3 | ||
| 1b | Frontline essential workers§ | 30 | 30 | 49 |
| Persons aged ≥75 years | 21 | 19 | ||
| 1c | Persons aged 65–74 years | 32 | 28 | 129 |
| Persons aged 16–64 years¶ with high-risk medical conditions | 110 | 81 | ||
| Essential workers§ not recommended for vaccination in Phase 1b | 57 | 20 | ||
| 2 | All persons aged ≥16 years¶ not previously recommended for vaccination | All remaining | All remaining | All remaining |
Abbreviation: COVID-19 = coronavirus disease 2019.
* Data sources for each group: health care personnel (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); long-term care facility residents (Minimum Data Set. Centers for Medicare & Medicaid Services; https://data.cms.gov/); frontline and other essential workers (American Community Survey, 2019; https://www.census.gov/programs-surveys/acs/data.html); age-specific groups (U.S. Census; https://data.census.gov/cedsci/); high-risk medical conditions (Behavioral Risk Factors Surveillance System, 2018; https://www.cdc.gov/brfss/annual_data/annual_data.htm).
† Excludes persons who were recommended to receive vaccine in an earlier phase (e.g., persons aged 65–74 years who are living in long-term care facilities or who are health care personnel, who would have been included in Phase 1a) and accounting for overlap between groups within the same phase (e.g., essential workers with high risk medical conditions).
§ Estimates for frontline and other essential workers are approximate and derived from prepandemic survey data; relative proportions will vary by state.
¶ As of December 18, only the Pfizer-BioNTech COVID-19 vaccine is authorized for use in persons aged 16–17 years.